Shigellosis

24 registered clinical trials studyying Shigellosis — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Completed	Study to Expand Safety and Immunogenicity Data With Shigella Bioconjugate Vaccine (Shigella4V2) in 9-month-old NCT06523231	LimmaTech Biologics AG	Phase 2
Recruiting	Shigella Sonnei 53G Human Infection Study in Kenyan Adults NCT05959616	University of Oxford	Phase 1
Active Not Recruiting	A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate Vaccine NCT06615375	LimmaTech Biologics AG	Phase 2
Recruiting	InvaplexAR-Detox and DmLT Adjuvant in the Netherlands and Zambia NCT05961059	Leiden University Medical Center	Phase 1
Active Not Recruiting	Safety and Efficacy of the Bacteriophage Preparation, ShigActive™, in a Human Experimental Model of Shigellosi NCT05182749	Intralytix, Inc.	Phase 1 / Phase 2
Active Not Recruiting	Tebipenem Trial in Children With Shigellosis NCT05121974	International Centre for Diarrhoeal Disease Research, Bangladesh	Phase 2
Completed	Controlled Human Infection Model Challenge/Rechallenge NCT04992520	PATH	Phase 1
Unknown	Efficacy, Immunogenicity and Safety of S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine in Volunteers Aged F NCT05156528	Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd	Phase 3
Completed	Ciprofloxacin Versus Azithromycin for Children Hospitalised With Dysentery NCT03854929	Oxford University Clinical Research Unit, Vietnam	Phase 4
Completed	A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infant NCT04056117	LimmaTech Biologics AG	Phase 1 / Phase 2
Completed	SF2a-TT15 Conjugate Vaccine in Healthy Adult Volunteers NCT02797236	Institut Pasteur	Phase 1
Completed	Phase 2b Challenge Study With the Bioconjugate Vaccine Flexyn2a NCT02646371	LimmaTech Biologics AG	Phase 2
Completed	Safety and Immunogenicity of Artificial Invaplex (Shigella Flexneri 2a InvaplexAR) NCT02445963	U.S. Army Medical Research and Development Command	Phase 1
Completed	Safety and Tolerability of a Bioconjugate Vaccine Against Shigella Flexneri 2a NCT02388009	LimmaTech Biologics AG	Phase 1
Completed	Diagnosis of Neglected Tropical Diseases Among Patients With Persistent Digestive Disorders NCT02105714	Swiss Tropical & Public Health Institute	—
Completed	Evaluate a New Shigella Sonnei Vaccine Administered Either by Intradermal, Intranasal or Intramuscular Route i NCT02034500	GSK Vaccines Institute For Global Health S.r.l.	Phase 1
Completed	A Phase 1, Dose Escalation Study, to Evaluate a New Shigella Sonnei Vaccine in Healthy Adults. NCT02017899	GSK Vaccines Institute For Global Health S.r.l.	Phase 1
Withdrawn	Shigella Sonnei OSPC-rDT Conjugate Vaccine NCT01399424	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 1
Completed	Shigella Sonnel O-SPC/rBRU Conjugate Vaccine NCT01369927	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 1
Completed	Safety Study of Inactivated Shigella Whole Cell Vaccine in Adults NCT01509846	PATH	Phase 1
Completed	Safety and Reactogenicity of Bioconjugate Vaccine to Prevent Shigella NCT01069471	GlycoVaxyn AG	Phase 1
Completed	Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and Assessment of Protection NCT00485134	U.S. Army Medical Research and Development Command	Phase 1 / Phase 2
Completed	Therapeutic Induction of Endogenous Antibiotics NCT00800930	International Centre for Diarrhoeal Disease Research, Bangladesh	Phase 2
Completed	Safety, Immunogenicity and Efficacy of Shigella Conjugate Vaccines in 1-4 Year Olds in Israel NCT00368316	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 3